Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The effect of the dose of aminoglutethimide on the suppression of oestrone, oestradiol and dehydroepiandrosterone sulphate (DHAS) levels was studied in 36 women with advanced postmenopausal breast cancer, all of whom received 20 mg hydrocortisone twice daily as replacement glucocorticoid. Aminoglutethimide (AG) 250 mg twice a day was as effective as AG 250 mg 3 times a day or AG 250 mg 4 times a day. Side-effects were less at the lowest dosage and were age-related. On-treatment oestrone levels were higher in non-responders to treatment. Lower doses of AG than are currently used may be as effective therapeutically.


Journal article


Eur J Cancer Clin Oncol

Publication Date





493 - 498


Adult, Aged, Aminoglutethimide, Breast Neoplasms, Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate, Drug Administration Schedule, Drug Therapy, Combination, Estradiol, Estrone, Female, Gonadal Steroid Hormones, Humans, Hydrocortisone, Menopause, Middle Aged